Drug intelligence / Profile preview

anti-CD137-6051

Development stage: Unknown
Lead developer: Protheragen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

anti-CD137-6051 is a monoclonal antibody agonist targeting CD137 (also known as 4-1BB), a costimulatory member of the tumor necrosis factor receptor superfamily. Developed by Protheragen, this therapeutic candidate is designed to enhance the activation, proliferation, and survival of cytotoxic T lymphocytes and natural killer cells within the tumor microenvironment. By triggering CD137 signaling, the antibody promotes a robust anti-tumor immune response. It is currently being evaluated in Phase I clinical trials for the treatment of various cancers.

Other names: Anti-CD137-6051Anti-CD-137-6051Anti-CD 137-6051

Targets

FCGR2B (Fc gamma receptor IIB)TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on anti-CD137-6051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD137-6051.

Explore the full profile